These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 24743472

  • 41. Prevalence of HIV and associated factors among visceral leishmaniasis cases in an endemic area of Northeast Brazil.
    Santos GO, Jesus NPS, Cerqueira-Braz JV, Santos VS, Lemos LMD.
    Rev Soc Bras Med Trop; 2019 Mar 18; 52():e20180257. PubMed ID: 30892399
    [Abstract] [Full Text] [Related]

  • 42. Comparison of serum cytokine levels in symptomatic and asymptomatic HIV-Leishmania coinfected individuals from a Brazilian visceral leishmaniasis endemic area.
    Guedes DL, Silva EDD, Castro MCAB, Júnior WLB, Ibarra-Meneses AV, Tsoumanis A, Adriaensen W, van Griensven J, Pereira VRA, Medeiros ZM.
    PLoS Negl Trop Dis; 2022 Jun 18; 16(6):e0010542. PubMed ID: 35714136
    [Abstract] [Full Text] [Related]

  • 43. Relapsing visceral leishmaniasis in a HIV-1 infected patient with advanced disease.
    Standaert D, Laurent F, Jonckheere S, Scheiff JM, Vandercam B, Yombi JC.
    Acta Clin Belg; 2013 Jun 18; 68(2):124-7. PubMed ID: 23967722
    [Abstract] [Full Text] [Related]

  • 44. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
    Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M.
    Clin Infect Dis; 2009 Jan 15; 48(2):e16-22. PubMed ID: 19093811
    [Abstract] [Full Text] [Related]

  • 45. Clinical aspects of visceral leishmaniasis caused by L. infantum in adults. Ten years of experience of the largest outbreak in Europe: what have we learned?
    Horrillo L, Castro A, Matía B, Molina L, García-Martínez J, Jaqueti J, García-Arata I, Carrillo E, Moreno J, Ruiz-Giardin JM, San Martín J.
    Parasit Vectors; 2019 Jul 24; 12(1):359. PubMed ID: 31340851
    [Abstract] [Full Text] [Related]

  • 46. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
    Molina I, Falcó V, Crespo M, Riera C, Ribera E, Curran A, Carrio J, Diaz M, Villar del Saz S, Fisa R, López-Chejade P, Ocaña I, Pahissa A.
    J Antimicrob Chemother; 2007 Oct 24; 60(4):837-42. PubMed ID: 17684055
    [Abstract] [Full Text] [Related]

  • 47. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
    Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, den Boer M, Davidson RN.
    Clin Infect Dis; 2006 Aug 01; 43(3):357-64. PubMed ID: 16804852
    [Abstract] [Full Text] [Related]

  • 48. [Visceral leishmaniasis: a comparative study of patients with and without human immunodeficiency virus infection].
    Reus S, Sánchez R, Portilla J, Boix V, Priego M, Merino E, Román F.
    Enferm Infecc Microbiol Clin; 1999 Dec 01; 17(10):515-20. PubMed ID: 10650648
    [Abstract] [Full Text] [Related]

  • 49. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
    Laguna F, López-Vélez R, Pulido F, Salas A, Torre-Cisneros J, Torres E, Medrano FJ, Sanz J, Picó G, Gómez-Rodrigo J, Pasquau J, Alvar J.
    AIDS; 1999 Jun 18; 13(9):1063-9. PubMed ID: 10397536
    [Abstract] [Full Text] [Related]

  • 50. The Risk and Predictors of Visceral Leishmaniasis Relapse in Human Immunodeficiency Virus-Coinfected Patients in Ethiopia: A Retrospective Cohort Study.
    Abongomera C, Diro E, Vogt F, Tsoumanis A, Mekonnen Z, Admassu H, Colebunders R, Mohammed R, Ritmeijer K, van Griensven J.
    Clin Infect Dis; 2017 Oct 30; 65(10):1703-1710. PubMed ID: 29020196
    [Abstract] [Full Text] [Related]

  • 51. PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.
    Zijlstra EE.
    PLoS Negl Trop Dis; 2014 Oct 30; 8(11):e3258. PubMed ID: 25412435
    [Abstract] [Full Text] [Related]

  • 52. Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study.
    Diro E, Ritmeijer K, Boelaert M, Alves F, Mohammed R, Abongomera C, Ravinetto R, De Crop M, Fikre H, Adera C, Colebunders R, van Loen H, Menten J, Lynen L, Hailu A, van Griensven J.
    PLoS Negl Trop Dis; 2015 Oct 30; 9(10):e0004087. PubMed ID: 26431253
    [Abstract] [Full Text] [Related]

  • 53. Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study.
    Kip AE, Blesson S, Alves F, Wasunna M, Kimutai R, Menza P, Mengesha B, Beijnen JH, Hailu A, Diro E, Dorlo TPC.
    J Antimicrob Chemother; 2021 Apr 13; 76(5):1258-1268. PubMed ID: 33677546
    [Abstract] [Full Text] [Related]

  • 54. Does timing of antiretroviral treatment influence treatment outcomes of visceral leishmaniasis in Northwest Ethiopia?
    Aderie EM, Diro E, Zachariah R, da Fonseca MS, Abongomera C, Dolamo BL, Ritmeijer K.
    Trans R Soc Trop Med Hyg; 2017 Mar 01; 111(3):107-116. PubMed ID: 28633331
    [Abstract] [Full Text] [Related]

  • 55. Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV.
    Adriaensen W, Cuypers B, Cordero CF, Mengasha B, Blesson S, Cnops L, Kaye PM, Alves F, Diro E, van Griensven J.
    EBioMedicine; 2020 May 01; 55():102748. PubMed ID: 32361248
    [Abstract] [Full Text] [Related]

  • 56. Frequency of Leishmania spp. infection among HIV-infected patients living in an urban area in Brazil: a cross-sectional study.
    Cunha MA, Celeste BJ, Kesper N, Fugimori M, Lago MM, Ibanes AS, Ouki LM, Neto EAS, Fonseca FF, Silva MAL, Júnior WLB, Lindoso JAL.
    BMC Infect Dis; 2020 Nov 25; 20(1):885. PubMed ID: 33238943
    [Abstract] [Full Text] [Related]

  • 57. Ultrasensitive real-time PCR for the clinical management of visceral leishmaniasis in HIV-Infected patients.
    Molina I, Fisa R, Riera C, Falcó V, Elizalde A, Salvador F, Crespo M, Curran A, López-Chejade P, Tebar S, Pérez-Hoyos S, Ribera E, Pahissa A.
    Am J Trop Med Hyg; 2013 Jul 25; 89(1):105-10. PubMed ID: 23629932
    [Abstract] [Full Text] [Related]

  • 58. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study.
    Pintado V, Martín-Rabadán P, Rivera ML, Moreno S, Bouza E.
    Medicine (Baltimore); 2001 Jan 25; 80(1):54-73. PubMed ID: 11204503
    [Abstract] [Full Text] [Related]

  • 59. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review.
    Cota GF, de Sousa MR, Rabello A.
    PLoS Negl Trop Dis; 2011 Jun 25; 5(6):e1153. PubMed ID: 21666786
    [Abstract] [Full Text] [Related]

  • 60. Impaired Thymic Output Can Be Related to the Low Immune Reconstitution and T Cell Repertoire Disturbances in Relapsing Visceral Leishmaniasis Associated HIV/AIDS Patients.
    Silva-Freitas ML, Corrêa-Castro G, Cota GF, Giacoia-Gripp C, Rabello A, Teixeira Dutra J, de Vasconcelos ZFM, Savino W, Da-Cruz AM, Santos-Oliveira JR.
    Front Immunol; 2020 Jun 25; 11():953. PubMed ID: 32508833
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.